Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
RESEARCH TOOLSreports
Crinetics Pharmaceuticals (CRNX) Stock Price & Analysis
209 Followers
CRNX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.23 - $31.00
Previous Close$28.69
Volume782.30K
Average Volume (3M)1.33M
Market Cap
$1.90B
Enterprise ValueN/A
Total Cash (Recent Filing)$264.53M
Total Debt (Recent Filing)$2.56M
Price to Earnings (P/E)-8.4
Beta0.55
Next Earnings
Nov 14, 2023EPS Estimate
-$0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.41
Shares Outstanding54,686,550
10 Day Avg. Volume2,245,942
30 Day Avg. Volume1,329,742
Standard Deviation0.14
R-Squared0.10
Alpha-0.00630
Financial Highlights & Ratios
Price to Book (P/B)6.37
Price to Sales (P/S)1588.01
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$49.44Price Target Upside76.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Crinetics Pharmaceuticals News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRNX FAQ
What was Crinetics Pharmaceuticals’s price range in the past 12 months?
Crinetics Pharmaceuticals lowest stock price was $15.23 and its highest was $31.00 in the past 12 months.
What is Crinetics Pharmaceuticals’s market cap?
Currently, no data Available
When is Crinetics Pharmaceuticals’s upcoming earnings report date?
Crinetics Pharmaceuticals’s upcoming earnings report date is Nov 14, 2023 which is in 47 days.
How were Crinetics Pharmaceuticals’s earnings last quarter?
Crinetics Pharmaceuticals released its earnings results on Aug 08, 2023. The company reported -$0.94 earnings per share for the quarter, missing the consensus estimate of -$0.866 by -$0.074.
Is Crinetics Pharmaceuticals overvalued?
According to Wall Street analysts Crinetics Pharmaceuticals’s price is currently Undervalued.
Does Crinetics Pharmaceuticals pay dividends?
Crinetics Pharmaceuticals does not currently pay dividends.
What is Crinetics Pharmaceuticals’s EPS estimate?
Crinetics Pharmaceuticals’s EPS estimate is -$0.91.
How many shares outstanding does Crinetics Pharmaceuticals have?
Crinetics Pharmaceuticals has 66,128,200 shares outstanding.
What happened to Crinetics Pharmaceuticals’s price movement after its last earnings report?
Crinetics Pharmaceuticals reported an EPS of -$0.94 in its last earnings report, missing expectations of -$0.866. Following the earnings report the stock price went down -3.889%.
Which hedge fund is a major shareholder of Crinetics Pharmaceuticals?
Among the largest hedge funds holding Crinetics Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds Crinetics Pharmaceuticals’s shares valued at 95M.
---
Crinetics Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.44 (76.38% Upside)
$49.44 (76.38% Upside)
Blogger Sentiment
Neutral
CRNX Sentiment 50%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $991.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.6%
Last 30 Days ▲ 51.3%
Last 30 Days ▲ 51.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.42%
12-Months-Change
Fundamentals
Return on Equity
-57.44%
Trailing 12-Months
Asset Growth
-30.46%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
---
Top 5 ETFs holding CRNX
Vanguard Total Stock Market ETF
$27.87M
iShares Core S&P Total U.S. Stock Market ETF
$1.29M
Schwab U.S. Broad Market ETF
$905.36K
iShares Russell 3000 ETF
$485.15K
Vanguard Russell 3000 ETF
$56.31K
Up to five ETFs with an Outperform Smart Score that hold CRNX. The ETFs are listed according to market value of CRNX within the ETF
Voyager Therapeutics
―
Revance Therapeutics
―
Rocket Pharmaceuticals
―
Mirati Therapeutics
―
---